- Home
- BMEA vs BTMD Comparison
BMEA vs BTMD Comparison
Compare BMEA & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- BTMD
- Stock Information
- Founded
- BMEA 2017
- BTMD 2012
- Country
- BMEA United States
- BTMD United States
- Employees
- BMEA N/A
- BTMD N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- BMEA Health Care
- BTMD Health Care
- Exchange
- BMEA Nasdaq
- BTMD Nasdaq
- Market Cap
- BMEA 114.3M
- BTMD 127.8M
- IPO Year
- BMEA 2021
- BTMD N/A
- Fundamental
- Price
- BMEA $1.93
- BTMD $3.37
- Analyst Decision
- BMEA Strong Buy
- BTMD Buy
- Analyst Count
- BMEA 10
- BTMD 2
- Target Price
- BMEA $15.70
- BTMD $6.00
- AVG Volume (30 Days)
- BMEA 559.5K
- BTMD 178.5K
- Earning Date
- BMEA 10-28-2025
- BTMD 11-11-2025
- Dividend Yield
- BMEA N/A
- BTMD N/A
- EPS Growth
- BMEA N/A
- BTMD 642.53
- EPS
- BMEA N/A
- BTMD 0.88
- Revenue
- BMEA N/A
- BTMD $199,073,000.00
- Revenue This Year
- BMEA N/A
- BTMD N/A
- Revenue Next Year
- BMEA N/A
- BTMD $4.85
- P/E Ratio
- BMEA N/A
- BTMD $3.83
- Revenue Growth
- BMEA N/A
- BTMD 6.32
- 52 Week Low
- BMEA $1.29
- BTMD $2.76
- 52 Week High
- BMEA $13.07
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- BMEA 55.47
- BTMD 48.22
- Support Level
- BMEA $1.77
- BTMD $3.27
- Resistance Level
- BMEA $2.08
- BTMD $3.54
- Average True Range (ATR)
- BMEA 0.11
- BTMD 0.16
- MACD
- BMEA 0.01
- BTMD 0.03
- Stochastic Oscillator
- BMEA 51.61
- BTMD 41.86
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.